Skip to main content
TipRanks
Go Ultimate75% OFF

Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

4 Followers
IN:CAPLIPOINT

Caplin Point Laboratories Limited

(NSE:CAPLIPOINT)

Select Model
Rating:71Outperform
Price Target:INR 2,305.00â–²(13.61% Upside)
Action:reiterated
Date:11/19/26

Caplin Point earns a solid above-average score driven primarily by exceptional fundamentals: a virtually debt-free balance sheet, consistent ~20% return on equity, double-digit revenue growth and industry-leading margins. Offsetting this is poor near-term technical positioning — the stock trades below all key moving averages with negative MACD momentum, though oversold RSI and Stochastic readings suggest selling may be stretched. Valuation at 23x earnings is fair for the growth and quality on offer, while the sub-0.5% dividend yield adds little support. Items to monitor are the forecast slowdown in FY2026 revenue growth and year-to-year volatility in free cash flow conversion tied to capex cycles.

Positive Factors
Consistent Revenue GrowthConsistent revenue growth indicates durable demand and effective execution across the company’s pharmaceutical portfolio and target markets. Continued top-line expansion can support operating scale, fund product development, and strengthen the company’s ability to compound earnings over the next several quarters.
Negative Factors
Recent Margin VolatilityRecent gross-margin pressure suggests that revenue growth has not translated into profit growth at a fully consistent rate. If this pattern persists, it could reduce operating leverage, temper earnings expansion, and weaken the benefit of the company’s otherwise strong profitability profile over the medium term.

Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%50%60%IN:CAPLIPOINT+6.92%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 154.24B
Dividend Yield
0.39%
Average Volume (3M)
14.85K
Price to Earnings (P/E)
22.4
Beta (1Y)
1.00
Revenue Growth
16.84%
EPS Growth
17.02%
Country
India
Employees
3,406
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive produc...

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Financials are the standout strength. Revenue compounded ~16% annually from ₹10.6B (FY2021) to ₹19.4B (FY2025) with net income more than doubling to ₹5.4B, supported by stable gross margins of 54–59% and net margins of 23–28% (Income Statement: 82). The balance sheet is a fortress — total debt of just ₹50.2M against ₹28.5B equity (D/E ~0.002) and consistently ~20% return on equity (Balance Sheet: 90). Cash flow is solid but less consistent: operating cash flow rose to ₹4.3B in FY2025 with free cash flow recovering to ₹2.4B, though conversion has swung between 29% and 73% of net income due to lumpy capex (Cash Flow: 75). The main watch item is projected FY2026 revenue growth slowing to 7.1% from prior double-digit rates.

Income Statement

82Very Positive

Balance Sheet

90Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue21.87B21.87B19.40B16.96B14.68B12.71B
Gross Profit11.15B10.50B11.38B9.40B7.89B6.99B
EBITDA8.53B8.76B6.53B5.54B4.43B3.97B
Net Income6.41B6.41B5.36B4.57B3.76B3.00B
Balance Sheet
Total Assets40.45B40.45B32.09B26.98B21.91B17.36B
Cash, Cash Equivalents and Short-Term Investments10.07B10.07B9.03B7.88B6.50B5.13B
Total Debt46.10M46.10M50.20M19.70M54.80M21.30M
Total Liabilities4.15B4.15B3.22B3.51B2.84B2.26B
Stockholders Equity35.86B35.86B28.50B23.16B18.80B14.84B
Cash Flow
Free Cash Flow1.60B3.37B2.41B1.73B779.00M2.46B
Operating Cash Flow2.54B5.85B4.32B3.18B2.72B3.37B
Investing Cash Flow-2.99B-6.45B-3.35B-3.20B-2.18B-3.77B
Financing Cash Flow-460.10M-455.90M-383.20M-380.70M-281.70M-407.10M

Caplin Point Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price2028.80

Price Trends

50DMA2486.08Negative
100DMA2532.72Negative
200DMA2195.66Negative

Market Momentum

MACD-85.06Positive
RSI27.50Positive
STOCH5.87Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 2028.80 is below the 20-day moving average (MA) of 2321.06, below the 50-day MA of 2486.08, and below the 200-day MA of 2195.66, indicating a bearish trend. The MACD of -85.06 indicates Positive momentum. The RSI at 27.50 is Positive, neither overbought nor oversold. The STOCH value of 5.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:CAPLIPOINT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:AKUMSIN:AKUMS73OutperformINR 112.12B29.30―0.43%17.50%14.74%
IN:CAPLIPOINTIN:CAPLIPOINT71OutperformINR 158.51B22.39―0.39%16.84%17.02%
IN:STARIN:STAR65NeutralINR 89.66B14.46―0.52%11.28%55.18%
IN:GRANULESIN:GRANULES59NeutralINR 199.33B28.46―0.21%21.75%36.70%
IN:PPLPHARMAIN:PPLPHARMA56NeutralINR 318.72B-151.67―0.06%9.43%-767.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:JUBLPHARMAIN:JUBLPHARMA49NeutralINR 148.36B56.26―0.53%18.30%-44.95%

* Healthcare Sector Average

Performance Comparison

0%50%IN:CAPLIPOINTIN:AKUMSIN:GRANULESIN:JUBLPHARMAIN:PPLPHARMAIN:STARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:CAPLIPOINT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:CAPLIPOINTCaplin Point Laboratories Limited2028.80122.726.44%
IN:AKUMSAkums Drugs and Pharmaceuticals Limited696.05283.7068.80%
IN:GRANULESGranules India Limited823.70292.2154.98%
IN:JUBLPHARMAJubilant Pharmova Limited934.05-135.96-12.71%
IN:PPLPHARMAPiramal Pharma Limited239.2552.9528.42%
IN:STARStrides Pharma Science Ltd964.9080.149.06%

Caplin Point Laboratories Limited Corporate Events

Caplin Point Laboratories Board Approves Unaudited September 2026 Results

Nov 12, 2026

Caplin Point Laboratories Limited’s board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The release also included an investor presentation and a limited review report.Standalo...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026